Channing Capital Management LLC Acquires 1,205 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Channing Capital Management LLC boosted its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 2.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 50,764 shares of the medical research company’s stock after purchasing an additional 1,205 shares during the quarter. Channing Capital Management LLC owned about 0.10% of Charles River Laboratories International worth $12,001,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in CRL. abrdn plc grew its position in Charles River Laboratories International by 872.0% during the fourth quarter. abrdn plc now owns 121,807 shares of the medical research company’s stock worth $28,795,000 after buying an additional 109,275 shares in the last quarter. Regency Capital Management Inc. DE acquired a new position in shares of Charles River Laboratories International in the fourth quarter valued at $3,703,000. WCM Investment Management LLC bought a new position in Charles River Laboratories International in the fourth quarter worth $1,396,000. DekaBank Deutsche Girozentrale boosted its stake in Charles River Laboratories International by 98.6% during the fourth quarter. DekaBank Deutsche Girozentrale now owns 14,094 shares of the medical research company’s stock worth $3,333,000 after buying an additional 6,997 shares in the last quarter. Finally, AMG National Trust Bank bought a new stake in Charles River Laboratories International in the 3rd quarter valued at $1,119,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

Insider Buying and Selling at Charles River Laboratories International

In related news, EVP Shannon M. Parisotto sold 5,882 shares of Charles River Laboratories International stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the completion of the sale, the executive vice president now directly owns 2,596 shares of the company’s stock, valued at $626,155.20. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, EVP Shannon M. Parisotto sold 5,882 shares of the stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $241.20, for a total value of $1,418,738.40. Following the sale, the executive vice president now directly owns 2,596 shares in the company, valued at approximately $626,155.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Victoria L. Creamer sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $253.70, for a total transaction of $1,268,500.00. Following the transaction, the executive vice president now owns 13,550 shares of the company’s stock, valued at approximately $3,437,635. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 14,932 shares of company stock valued at $3,693,663. 1.30% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

CRL has been the topic of several recent research reports. Argus lifted their target price on shares of Charles River Laboratories International from $240.00 to $290.00 and gave the company a “buy” rating in a research report on Monday, March 18th. Robert W. Baird upped their price objective on Charles River Laboratories International from $252.00 to $268.00 and gave the company an “outperform” rating in a research note on Thursday, February 15th. UBS Group raised their target price on Charles River Laboratories International from $270.00 to $290.00 and gave the stock a “buy” rating in a research report on Thursday, February 15th. Citigroup upped their price target on Charles River Laboratories International from $215.00 to $250.00 and gave the company a “neutral” rating in a research report on Thursday, February 15th. Finally, Evercore ISI increased their price objective on Charles River Laboratories International from $260.00 to $265.00 and gave the stock an “outperform” rating in a research note on Thursday, February 15th. Five equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $253.23.

Charles River Laboratories International Price Performance

CRL traded up $3.58 during midday trading on Friday, hitting $233.47. The company had a trading volume of 466,193 shares, compared to its average volume of 482,082. Charles River Laboratories International, Inc. has a twelve month low of $161.65 and a twelve month high of $275.00. The company has a market capitalization of $12.03 billion, a PE ratio of 25.35, a P/E/G ratio of 1.83 and a beta of 1.44. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.16 and a current ratio of 1.52. The firm’s 50-day simple moving average is $252.23 and its 200-day simple moving average is $224.20.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.46 earnings per share for the quarter, topping the consensus estimate of $2.39 by $0.07. The firm had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $991.25 million. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. Charles River Laboratories International’s revenue was down 7.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.98 EPS. Equities research analysts predict that Charles River Laboratories International, Inc. will post 11.01 EPS for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).